Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-AssembliesNowadays, personalized cancer therapy relies on small molecules, monoclonal antibodies, or antibody鈥揹rug conjugates (ADC). Many nanoparticle (NP)-based drug delivery ...
Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond In this paper we review the results of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) therapy in metastatic colorectal cancer (mC... A Ballestrero,A Garuti,G Cir...
To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nan
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–7. CrossRef Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different...
Drugs targeting EGFR in malignancies were initially developed in the 1980s, which lead to the development of anti-EGFR monoclonal antibodies and small molecule EGFR tyrosine kinase inhibitors (TKIs) [6–9]. EGFR is overexpressed in many solid tumors and this over expression correlates to advanced ...
Anti-epidermal growth factor receptor (EGFR) antibodies (anti-EGFR-Ab) are effective in a subgroup of patients (pts) with metastatic colorectal cancer (CRC). Activating KRAS or NRAS mutations in codons 12, 13, 59, 61, 117, and 146 have been associated with primary resistance in randomized ...
in a variety of epithelial tumors such as CRC [10]. Therapeutically, EGFR can be targeted by small-molecule tyrosine kinase inhibitors (e.g., erlotinib and gefitinib) or by monoclonal antibodies (mAbs) [8]. Currently, three monoclonal antibodies (cetuximab, panitumumab, and necitumumab) have ...
Analogous to human breast cancer, canine mammary gland tumors are valuable for predicting disease progression. Numerous microRNA varieties are observed in instances of human breast cancer and canine mammary gland tumors. A thorough understanding of the roles of microRNAs in canine mammary gland tumors ...
A significant fraction of non-small cell lung cancer (NSCLC) cases are due to oncogenic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Anti-EGFR antibodies have shown limited clinical benefit for NSCLC, whereas tyrosine kinase inhibitors (TKIs) are ...
PUMA induction and p73 activation are abrogated in CRC cells with acquired resistance to anti-EGFR antibodies due to KRAS alterations. Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS-mediated resistance to anti-EGFR antibodies in vitro and in vivo by ...